Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell

NCT05510219 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT05510219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05510219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 31, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intravenous infusion reaction, obinutuzumab, rapid infusion